Previous 10 | Next 10 |
Aeglea BioTherapeutics (AGLE -6.5%) is trading lower for the third straight session after announcing that Sara Brownstein, a Class I director of its Board, informed the company on Wednesday that she would resign, effective Feb. 09. “The Company believes Ms. Brownstein’s resignat...
Gainers: Dermata Therapeutics (NASDAQ:DRMA) +35%. Innoviva (NASDAQ:INVA) +11%. Mainz Biomed (NASDAQ:MYNZ) +9%. Regional Health Properties (NYSE:RHE) +9%. Envista Holdings (NYSE:NVST) +8%. Losers: InfuSystem Holdings (NYSE:INFU) -22%. Sea...
Aeglea BioTherapeutics (NASDAQ:AGLE) withdraws its previously announced, proposed public offering. Company is capitalized with cash and cash equivalents of $95M as of December 31, 2021, which we believe will be sufficient to fund our operations into Q1 2023. For further details see: ...
Aeglea BioTherapeutics Withdraws Public Offering PR Newswire AUSTIN, Texas , Feb. 10, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme ther...
Aeglea BioTherapeutics (NASDAQ:AGLE) announced a proposed underwritten public offering of shares and, in lieu of stock, pre-funded warrants to purchase shares to certain investors. AGLE expects to grant the underwriters a 30-day option to purchase additional shares. Net proceeds, together wit...
Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1 Deficiency PR Newswire AUSTIN, Texas , Jan. 25, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new...
Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022 PR Newswire AUSTIN, Texas , Jan. 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of hu...
Last week was an especially rough one for several small biotechs. Disappointing news for Aeglea BioTherapeutics (NASDAQ: AGLE) , Bolt Biotherapeutics (NASDAQ: BOLT) , and Reata Pharmaceuticals (NASDAQ: RETA) caused shares of all three companies to plunge. In this ...
Aeglea achieved primary endpoint in reducing arginine levels with its drug pegzilarginase for ARG1-D, which in turn reduced ammonia in the blood plasma, by an average of 80%. BLA filing of pegzilarginase for patients with ARG1-D is expected to occur in 1st half of 2022. Additional...
Shares of Aeglea BioTherapeutics (NASDAQ: AGLE) , a clinical-stage biopharmaceutical company , are falling today in response to mixed clinical-trial data. Investors nervous about the future of the company's lead candidate pushed the stock 36.6% lower as of 11:53 a.m. ET on Monda...
News, Short Squeeze, Breakout and More Instantly...
Aeglea BioTherapeutics Inc. Company Name:
AGLE Stock Symbol:
NASDAQ Market:
Aeglea BioTherapeutics Inc. Website:
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire Company will begin trading on Nasdaq under trading sy...
2023-11-20 05:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β...